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Abstract
Objective:  To  review  the  literature  on  sialorrhea  in  children  with  cerebral  palsy.
Source of  data:  Non-systematic  review  using  the  keywords  ‘‘sialorrhea’’  and  ‘‘child’’  carried
out in  the  PubMed®,  LILACS®,  and  SciELO® databases  during  July  2015.  A  total  of  458  articles
were obtained,  of  which  158  were  analyzed  as  they  were  associated  with  sialorrhea  in  children;
70 had  content  related  to  sialorrhea  in  cerebral  palsy  or  the  assessment  and  treatment  of
sialorrhea  in  other  neurological  disorders,  which  were  also  assessed.
Data synthesis: The  prevalence  of  sialorrhea  is  between  10%  and  58%  in  cerebral  palsy  and  has
clinical and  social  consequences.  It  is  caused  by  oral  motor  dysfunction,  dysphagia,  and  intra-
oral sensitivity  disorder.  The  severity  and  impact  of  sialorrhea  are  assessed  through  objective
or subjective  methods.  Several  types  of  therapeutic  management  are  described:  training  of
sensory awareness  and  oral  motor  skills,  drug  therapy,  botulinum  toxin  injection,  and  surgical
treatment.
Conclusions:  The  most  effective  treatment  that  addresses  the  cause  of  sialorrhea  in  children
with cerebral  palsy  is  training  of  sensory  awareness  and  oral  motor  skills,  performed  by  a  speech
therapist.  Botulinum  toxin  injection  and  the  use  of  anticholinergics  have  a  transient  effect  and
are adjuvant  to  speech  therapy;  they  should  be  considered  in  cases  of  moderate  to  severe  sial-
orrhea or  respiratory  complications.  Atropine  sulfate  is  inexpensive  and  appears  to  have  good
clinical response  combined  with  good  safety  proﬁle.  The  use  of  trihexyphenidyl  for  the  treat-
ment of  sialorrhea  can  be  considered  in  dyskinetic  forms  of  cerebral  palsy  or  in  selected  cases.
© 2016  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  This  is  an  open
access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
 Please cite this article as: Scofano Dias BL, Fernandes AR, Maia Filho HS. Sialorrhea in children with cerebral palsy. J Pediatr (Rio J).
2016;92:549--58.
 Study carried out at Rede SARAH de Hospitais de Reabilitac¸ão, Rio de Janeiro, RJ, Brazil.
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Sialorreia  em  crianc¸as com  paralisia  cerebral
Resumo
Objetivo:  Revisar  a  literatura  referente  a  sialorreia  em  crianc¸as  com  paralisia  cerebral.
Fonte de  dados: Revisão  não  sistemática  utilizando  as  palavras-chave  ‘‘sialorreia’’  e  ‘‘crianc¸a’’
realizada  nas  bases  de  dados  Pubmed®,  Lilacs®  e  Scielo®  em  julho  de  2015.  Foram  recuper-
ados 458  artigos,  158  foram  analisados  por  terem  relac¸ão  com  sialorreia  em  crianc¸as,  70  com
conteúdo  relativo  à  sialorreia  na  paralisia  cerebral  ou  a  avaliac¸ão  e  tratamento  da  sialorreia
em outros  distúrbios  neurológicos  foram  aproveitados.
Síntese  dos  dados:  A  sialorreia  tem  prevalência  entre  10%  e  58%  na  paralisia  cerebral  e  implica
em consequências  clínicas  e  sociais.  É  causada  por  disfunc¸ão  motora  oral,  disfagia  e  distúrbio  da
sensibilidade  intraoral.  A  gravidade  e  o  impacto  da  sialorreia  são  avaliados  através  de  métodos
objetivos ou  subjetivos.  Estão  descritas  diversas  formas  de  manejo  terapêutico:  treino  para
consciência  sensorial  e  habilidades  motoras  orais,  terapia  farmacológica,  injec¸ão  de  toxina
botulínica  e  tratamento  cirúrgico.
Conclusões:  O  tratamento  mais  eﬁcaz  e  que  aborda  a  causa  da  sialorreia  nas  crianc¸as  com
paralisia cerebral  é  o  treino  para  consciência  sensorial  e  habilidades  motoras  orais,  realizado  por
um fonoaudiólogo.  Injec¸ão  de  toxina  botulínica  e  o  uso  de  anticolinérgicos  têm  efeito  transitório
e são  auxiliares  ao  tratamento  fonoaudiológico  ou  devem  ser  consideradas  nos  casos  de  sialorreia
moderada  a  grave  ou  com  complicac¸ões  respiratórias.  O  sulfato  de  atropina  tem  baixo  custo
e parece  ter  boa  resposta  clínica  com  bom  perﬁl  de  seguranc¸a.  O  uso  de  triexifenidil  para  o
tratamento  da  sialorreia  pode  ser  considerado  nas  formas  discinéticas  de  paralisia  cerebral  ou
em casos  selecionados.
©  2016  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Este e´ um  artigo
Open Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-nc-nd/4.
0/).
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artery.  Salivary  secretion  is  regulated  indirectly  by  thentroduction
ialorrhea  is  the  involuntary  loss  of  saliva  and  oral  content1,2
hat  usually  occurs  in  infants;  however,  at  24  months  of
ge  children  with  typical  development  should  have  the
bility  to  perform  most  activities  without  loss  of  saliva.3
fter  the  age  of  4  years,  sialorrhea  is  abnormal  and  often
ersists  in  children  with  neurological  disorders,  including
euromuscular  incoordination  of  swallowing  and  intellec-
ual  disabilities.1 The  term  cerebral  palsy  (CP)  describes
 group  of  movement  and  posture  development  disorders,
ith  activity  restrictions  or  motor  disabilities  caused  by  mal-
ormations  or  injuries  that  occur  in  the  developing  fetal  or
hild’s  brain.4,5 Worldwide,  the  prevalence  of  CP  is  1--5  per
000  live  births,  representing  the  most  common  cause  of
otor  disability  in  children.6 The  prevalence  of  sialorrhea
n  CP  is  seldom  studied,  and  the  results  cannot  be  compared
ue  to  variation  in  the  study  designs  and  patient  selection.1
ome  authors  reported  a  prevalence  of  10--58%,7--10 thus  it
s  reasonable  to  accept  that  one  in  three  patients  with  CP
as  drooling  at  some  degree.1
Although  underestimated,  sialorrhea  implies  clinical  and
ocial  consequences  and  has  several  impacts  related  to  the
verall  health  of  children  with  CP,  regarding  dysphagia  and
espiratory  health,  their  socio-emotional  development,  and
motional  and  work  overload  for  families  and  caregivers.
This  non-systematic  review  aims  to  update  the  profes-
ionals  involved  in  the  care  of  children  with  CP  in  relation
o  the  literature  on  sialorrhea  in  these  patients;  it  was  car-
ied  out  using  the  keywords  ‘‘sialorrhea’’  and  ‘‘child’’  in  the
h
u
iubMed®,  LILACS®,  and  SciELO® databases  during  July  2015.
 total  of  458  articles  were  retrieved,  of  which  158  were
nalyzed,  as  they  were  associated  with  sialorrhea  in  chil-
ren;  70  were  related  to  sialorrhea  in  cerebral  palsy  or  the
ssessment  and  treatment  of  sialorrhea  in  other  neurological
isorders,  which  were  also  assessed.
hysiology  of  salivation
he  parotid  glands  produce  more  serous,  watery  saliva  as
 result  of  stimulation  during  meals.  The  sublingual  and
ubmandibular  glands  produce  more  viscous  saliva,  more
onstantly,  throughout  the  day.11,12 On  average,  a  person
wallows  approximately  600  mL  of  saliva  every  day;  how-
ver,  in  some  individuals,  this  volume  can  reach  up  to
000  mL/day.11 Afferents  of  the  ﬁfth,  seventh,  ninth,  and
enth  cranial  nerves  reach  the  solitary  tract  and  saliva-
ory  nuclei  in  the  medulla.  The  parasympathetic  stimulation
eaches  the  submandibular  salivary  glands  through  the  sev-
nth  cranial  nerve  and  the  parotid  through  the  ninth  nerve.
The  preganglionic  sympathetic  ﬁbers  originate  at  the
ateral  intermediate  column  of  the  ﬁrst  and  second  tho-
acic  segments  and  connect  with  the  postganglionic  ﬁbers
n  the  upper  cervical  sympathetic  ganglion.  These  post-
anglionic  sympathetic  ﬁbers  reach  the  salivary  glands
assing  through  the  section  along  the  external  carotidypothalamus-solitary  circuit  and  by  effects  directly  mod-
lated  by  tactile,  mechanical,  and  gustatory  reﬂexes.  It
s  questionable  whether  an  interruption  can  occur  in  this
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tSialorrhea  in  children  with  cerebral  palsy  
regulatory  mechanism  as  part  of  encephalopathy  in  CP.11
Sialorrhea  may  vary  from  minute  to  minute,  depending  on
factors  such  as  hunger,  thirst,  fatigue,  anxiety,  emotional
state,  and  the  circadian  rhythm  of  salivary  production.1
Predisposing  factors,  physiopathology,  and  etiology
Reid  et  al.  analyzed  the  predisposing  factors  of  sialor-
rhea  in  children  with  CP  (385  individuals)  aged  7--
14  years  of  age,  which  include  the  following:  non-spastic
types,  the  quadriplegic  topographical  pattern,  absence  of
cervical  control,  severe  difﬁculties  in  gross  motor  coor-
dination/function,  epilepsy,  intellectual  disability,  lack  of
speech,  open  anterior  bite,  and  dysphagia.13
Currently,  it  is  widely  accepted  that  sialorrhea  in  chil-
dren  with  CP  is  not  caused  by  hypersalivation,  but  by  oral
motor  dysfunction,  dysphagia,  and/or  intraoral  sensitivity
disorder.1,3,9,11,12 Senner  et  al.  published  a  study  that  com-
pared  groups  of  children  with  CP  with  sialorrhea  (n  =  14);
children  with  CP  without  sialorrhea  (n  =  14),  and  children
with  normal  neurodevelopment  (n  =  14)  through  quantiﬁca-
tion  of  saliva  using  the  Saxon  test  described  by  Kohler  et  al.
in  1985;14 the  results  showed  lower  scores  in  oral  motor  func-
tion  without  excess  saliva  production  in  the  CP  group  with
sialorrhea,  suggesting  that  the  hypersalivation  is  not  one  of
the  factors  responsible  for  sialorrhea  in  CP.3 Erasmus  et  al.
studied  groups  of  children  with  CP  (n  =  100)  and  healthy  chil-
dren  (n  =  61)  through  collection  of  saliva  using  the  method
described  by  Rottevel  et  al.15 and  concluded  that  there  were
no  differences  between  salivary  ﬂow  rates  in  both  groups  of
patients.11
A  proper  swallowing  reﬂex  is  essential  for  the  swal-
lowing  of  saliva.  This  complex,  fundamental  function  is
mediated  by  orofacial  neuromuscular  systems,  and  involves
a  series  of  sequential  reﬂexes  and  coordinated  movements
of  the  muscles  of  the  mandible,  lips,  tongue,  pharynx,
larynx,  and  esophagus.12 Several  studies  have  shown  a  pos-
itive  correlation  between  sialorrhea  in  children  with  CP
and  the  following  factors:  difﬁculties  in  the  formation  of
the  food  bolus,3,7 inefﬁcient  labial  sealing,  suction  disor-
der,  increased  food  residue,3,16 difﬁculty  controlling  the  lips,
tongue,  and  mandible,3,8 reduced  intraoral  sensitivity,3,17
reduced  frequency  of  spontaneous  swallowing,18 esophageal
phase  dysphagia,3,7 and  dental  malocclusion.3,19 Signiﬁcant
negative  correlations  have  been  found  between  sialorrhea
and  chewing  capacity,  as  well  as  other  swallowing  skills
in  general.3 Other  factors,  all  common  in  CP,  inﬂuence
the  presence  and  severity  of  sialorrhea:  open  mouth  posi-
tion,  inadequate  body  posture,  particularly  of  the  head,
intellectual  disabilities,  emotional  state,  and  degree  of
concentration.1,12,20
Association  between  sialorrhea  and
gastroesophageal  reﬂux  disease  (GERD)
Saliva  plays  an  important  role  in  protecting  the  esophageal
mucosa  against  lesions  caused  by  GERD.  In  children  with  sial-
orrhea,  the  constant  loss  of  saliva  can  impair  the  removal  of
gastric  acid  reﬂux  into  the  esophagus,  which  can  perpetu-
ate  esophageal  dysmotility  and  esophagitis.3,21 Heine  et  al.,
in  a  study  carried  out  in  1996,  showed  that  approximately
w
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ne-third  of  the  24  children  with  sialorrhea  had  evidence  of
ERD  in  the  24-hour  pH  monitoring  or  esophagoscopy.  In  this
tudy,  drug  treatment  with  cisapride  and  ranitidine  for  GERD
id  not  reduce  the  severity  and  frequency  of  sialorrhea  in
ost  children,  and  in  the  authors’  opinion,  saliva  secretion
timulated  by  GERD  should  have  clinical  signiﬁcance  only  in
hose  patients  with  signiﬁcant  esophagitis.21
For  Erasmus  et  al.,  chemical  irritation  caused  by  GERD
an  lead  to  increased  production  of  saliva  through  the
ediation  of  the  parasympathetic  nervous  system  and  vago-
agal  reﬂex,  aiming  to  protect  the  oropharyngeal  and
sophageal  mucosa.  In  children  with  oral  motor  dysfunc-
ion,  this  increase  in  saliva  production  could  accumulate
n  the  pharynx  and/or  esophagus,  increasing  the  risk  of
spiration.  In  the  authors’  opinion,  it  is  still  a  matter  of
ebate  whether  GERD  alone  can  cause  severe  sialorrhea  and
f  GERD  treatment  can  reduce  its  intensity  in  children  with
P.10
lassiﬁcation  and  clinical,  social,  and  family
mplications
rom  a  clinical  point  of  view,  sialorrhea  can  be  classiﬁed  as
nterior  and  posterior;  both  can  occur  separately  or  simulta-
eously.  Anterior  sialorrhea  is  the  unintentional  loss  of  saliva
rom  the  mouth.  Posterior  sialorrhea  is  the  ﬂowing  of  saliva
rom  the  tongue  to  the  pharynx.1,10,22
Anterior  sialorrhea  can  lead  to  psychosocial,  physical,
nd  educational  consequences.  One  of  them  is  social  iso-
ation,  which  can  have  negative  effects  on  self-esteem.
he  most  severely  affected  children  may  have  an  unpleas-
nt  odor,  and  may  be  rejected  by  their  peers  and  even  by
heir  caregivers.  Individuals  may  be  perceived  negatively
nd  their  intellectual  capacity  may  be  underestimated.
he  extent  of  this  impact  varies  according  to  sociocul-
ural  characteristics,  depending  on  age  and  cognitive  ability.
evere  anterior  sialorrhea  requires  frequent  changes  of
lothes  and  can  damage  books,  computers,  and  keyboards,
hreatening  essential  education  and  communication  tools.
here  can  also  be  perioral  infections  and  damage  to  the
entition.1,3,10,23--28 These  consequences  affect  the  lives  of
atients  and  also  have  an  impact  on  the  quality  of  life  of
amilies  and  caregivers.  A  Dutch  group  demonstrated  the
onsiderable  demands  placed  on  caregivers  in  terms  of  work-
oad,  such  as  having  to  frequently  remind  the  individual
o  swallow  saliva,  clean  the  excess  saliva  on  the  mouth,
hin,  and  other  areas,  and  change  and  wash  towels  and
lothes.27,28
Posterior  sialorrhea  occurs  in  children  with  more  severe
haryngeal  phase  dysphagia.  These  children  are  at  risk  for
aliva  aspiration,  which  can  cause  recurrent  pneumonia
nd  may  even  go  undiagnosed  before  signiﬁcant  lung  injury
evelops.10 Park  et  al.  described  two  cases  in  which  saliva
spiration  into  the  tracheobronchial  tree  was  successfully
ocumented  through  a  radionuclide  assessment  known  as
 salivagram.  This  same  method  was  used  and  showed  a
otal  reduction  in  saliva  aspiration  after  botulinum  toxin
as  applied  to  patients’  salivary  glands.29 Vijayasekaran
t  al.  studied  a  group  of  62  children  submitted  to  surgi-
al  treatment  for  sialorrhea,  and  showed  an  increase  in  the
ean  oxygen  saturation  and  reduction  in  the  frequency  of
552  Scofano  Dias  BL  et  al.
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Figure  1  Interaction  between  the  clinical  aspects  involved  in  the  health  of  children  with  CP.  GERD,  gastroesophageal  reﬂux
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reduction  in  social-affective  and  health  impacts  caused  byisease; CPD,  chronic  pulmonary  disease.
neumonia.  Thus,  therapeutic  interventions  can  effectively
mprove  respiratory  health  in  these  patients.30
ialorrhea  assessment
linical  assessment
he  different  clinical  aspects  involved  in  the  health  sta-
us  of  children  with  CP  can  inﬂuence  the  occurrence  and
everity  of  sialorrhea  and,  conversely,  their  severity  can  be
nﬂuenced  by  their  presence  (Fig.  1).  Therefore,  when  eval-
ating  sialorrhea,  these  several  factors  (Table  1)  should  be
ctively  assessed  by  history-taking  and  through  observation
f  the  child.1
ethods  of  sialorrhea  measurement
t  is  difﬁcult  to  measure  sialorrhea.  The  child  must  not  real-
ze  that  he/she  is  being  observed  and  should  be  assessed
uring  everyday  situations.  Nevertheless,  it  is  necessary  to
uantify  the  frequency  and  severity  of  sialorrhea,  as  well
s  its  impact  on  the  quality  of  life  of  children  and  their
aregivers.  The  severity  and  impact  of  sialorrhea  can  be
valuated  through  objective  or  subjective  methods.31
Objective  methods  include  measurement  of  salivary
ow  and  direct  observation  of  saliva  loss;  some  of  these
echniques  are  described  in  Table  2.12,21,25,26,31--35 The
evelopment  of  direct  (objective)  measurement  methods
or  anterior  sialorrhea,  which  are  validated  and  actually
a
p
a
ceasible,  are  still  a  challenge  both  in  the  research  ﬁeld  and
n  clinical  practice.31
Subjective  scales  are  useful  and  appropriate  methods  to
easure  changes  in  sialorrhea,  because  the  impact  on  fam-
lies,  caregivers,  and  the  patients  themselves  is  of  utmost
mportance  when  assessing  satisfaction  with  the  effective-
ess  of  any  treatment.  According  to  some  researchers,
he  deﬁnitive  method  for  evaluating  the  effectiveness  of
ny  treatment  for  sialorrhea  is  one  that  measures  how
uch  the  life  of  the  caregiver  has  been  facilitated  and
hat  quantiﬁes  the  improvement  in  the  child’s  quality  of
ife.33,36 Subjective  scales  such  as  the  Drooling  Rating  Scale,
he  Drooling  Frequency  and  Severity  Scale,  visual  analog
cales,  and  the  Drooling  Impact  Scale31,33,36 are  ﬁlled  out  by
atients  or  their  caregivers,  which  express  their  qualitative
nd  quantitative  impressions  of  the  severity  and  impact  of
ialorrhea.31
reatment
bjectives
he  main  objectives  in  the  treatment  of  sialorrhea  are:nterior  sialorrhea;  reduction  in  health  impacts  caused  by
osterior  sialorrhea;  improved  quality  of  life  for  patients
nd  caregivers;  and  reduction  in  the  burden  experienced  by
aregivers.
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Table  1  Clinical  factors  to  be  investigated.
Clinical  and  social-emotional  history
Motivation,  physical,  and  cognitive  ability  to  try  to  reduce  sialorrhea
Use of  medications  (anticonvulsants,  benzodiazepines,  neuroleptics)
Neurological  examination  (including  state  of  alertness,  cranial  nerves,  overall  motor  skills,  posture,  and  tone)
Orofacial assessment  (signs  of  upper  airway  obstruction)
Oral hygiene,  dental  occlusion  and  health,  labial  sealing
Language  (dysarthria,  dyspraxia)  and  communication  skills  in  general
Cognition
Respiratory  health  (hypersecretion,  bronchospasm,  and  recurrent  infections)/atopy
Presence of  GERD
Presence  and  assessment  of  dysphagia
Nutrition
GERD, gastroesophageal reﬂux disease.
Table  2  Objective  methods  to  measure  sialorrhea.
Technique  Method  Description
Drooling  quotient
(DQ)21,34
Saliva  collection  and  use  of  its  own  formula
for quantiﬁcation
At  every  15  s,  in  a  15-minute  period  (60
observations)  the  presence  or  absence  of
sialorrhea  was  observed.  DQ  {%}  =  100  ×  the
number  of  episodes  of  sialorrhea/60
observations
Sochaniwskyj’s
technique12,35
Saliva  collection  and  use  of  its  own  formula
for quantiﬁcation
Collection  of  saliva  that  leaked  through  the
mouth  and  reached  the  chin,  using  a  glass,
for a  30-minute  period
Thomas-Stonnel  and
Greenberg
scale12,26
Direct  observation  of  the  examiner
quantiﬁed  through  a  severity  scale
1  -- Dry  lips  (no  sialorrhea);
2 -- Wet  lips  (mild  sialorrhea);
3  --  Wet  lips  and  chin  (moderate  sialorrhea);
4 -- Wet  clothing  around  the  neck  (severe
sialorrhea);
5 -- Wet  clothing,  hands,  and  objects
(profuse  sialorrhea)
Others31 Measuring  the  weight  of  the  container  used Use  of  collection  units,  towels,  and  diapers
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ifor direct  collection  of  saliva
Quality  of  life  and  burden  on  family/caregivers,
self-esteem,  and  child’s  health
In  general,  after  several  treatment  modalities,  the  demands
related  to  the  care  of  these  children  are  reduced,  partic-
ularly  regarding  the  frequency  of  the  need  to  clean  the
mouth,  lips,  and  chin;  the  number  of  changes  of  towels
and  clothes;  and  damage  to  books,  school  supplies,  toys,
and  electronic  equipment.36,37 Additionally,  reduction  in
sialorrhea  improves  social  contact  between  children  and
their  peers.  Even  in  children  with  intellectual  disabilities,
a  German  study  has  shown  that  the  perception  of  parents
concerning  their  children’s  satisfaction  in  relation  to  their
physical  appearance  and  life  in  general  can  improve  after
therapeutic  interventions.36,38 van  der  Burg  et  al.  published
a  study  in  which  they  evaluated  changes  in  quality  of  life
and  necessity  of  care  as  a  result  of  sialorrhea  treatment.  The
impact  of  sialorrhea  was  investigated  before  and  after  treat-
ment,  using  a  questionnaire  designed  speciﬁcally  for  this
study.  The  results  demonstrated  that  the  decrease  in  sali-
vary  ﬂow  had  a  signiﬁcantly  positive  effect  on  the  need  for
daily  care.  The  authors  conclude  that  reduced  salivary  ﬂow
should  not  be  the  only  goal  in  the  treatment  of  sialorrhea.  It
a
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s
oor dental  cotton  rolls
s  recommended  that  the  several  therapeutic  modalities  be
ssessed  in  relation  to  the  impact  they  bring  to  the  patient’s
aily  life.38
herapeutic  modalities
he  literature  describes  several  forms  of  therapeutic  man-
gement.  The  advantages  and  disadvantages  of  the  main
reatment  modalities  are  summarized  in  Table  3.
raining  of  sensory  awareness  and  oral  motor  skills
or  children  capable  of  obeying  commands  and  cooperat-
ng  with  the  training,  this  is  the  foundation  of  intervention
nd  should  be  tested  before  other  treatment  options.  Initial
aneuvers  include  improvements  in  the  sitting  position,  lip
ovements,  and  closing  of  the  mandible  and  tongue.  In  its
implest  form,  it  consists  of  exercises  that  are  carried  out
n  a  playful  manner,  such  as  the  use  of  different  textures
round  the  mouth  (ice  cubes,  electric  toothbrush,  etc.)  to
timulate  sensory  awareness  and  exercises  to  improve  lip
ealing  and  tongue  movement  (using  a straw,  lipstick  kisses
n  paper,  ﬁlling  party  balloons,  etc.).  The  constant  guidance
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Table  3  Advantages  and  disadvantages  of  the  main  therapeutic  modalities.
Therapeutic
modalities
Advantages  Disadvantages
Training  of  sensory
awareness  and
oral  motor  skills
Treats  the  underlying  cause;
Long-lasting  effect
Depends  on  the  intellectual  capacity;
Requires  access  to  regular  therapy  and  a  trained
professional
Botulinum toxin
use
High  efﬁcacy;
Safe
Transient  effect;
Requires  equipment  and  trained  multidisciplinary
staff;
Requires  good  clinical  condition  for  sedation  or
anesthesia;
Does not  treat  the  underlying  cause
Surgical treatment Deﬁnitive  efﬁcacy Deﬁnitive  side  effects;
Requires  general  anesthesia;
Demands  equipment  and  trained  surgical  team;
Does  not  treat  the  underlying  cause.
Pharmacological
treatment with
anticholinergics
Proven  effectiveness;
Self-administered  (by  the  patient  or
caregiver);
Does not  require  sedation  or  anesthesia;
Frequently  anticholinergic  effects  (vomiting,
diarrhea,  irritability,  changes  in  mood  and  insomnia);
Does  not  treat  the  underlying  cause.
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f  the  speech  therapist  is  necessary.  Unlike  children  with
ore  severe  neurological  symptoms  and  less  capacity  for
ooperation  and  understanding,  those  with  mild  sialorrhea
an  achieve  signiﬁcant  beneﬁts  through  such  a  program.39
ody  modiﬁcation  through  biofeedback
ody  modiﬁcation  through  biofeedback  is  based  on  the  mon-
toring  of  the  target  muscle  group  for  electromyographic
timulation.  When  the  muscle  contracts,  electromyography
nforms  of  the  change  in  muscle  activity  through  acoustic
r  light  signals.  Thus,  the  patient  can  consciously  correct  or
mprove  certain  components  of  swallowing.  The  technique
an  have  a  positive  impact  on  patient  training  and  improving
romotor  function.12,20
rthodontic  therapy
t  should  be  used  as  complementary  to  any  other  treatment,
nd  aims  to  prevent  or  correct  an  anterior  open  bite  and
ther  vertical  occlusion  abnormalities.12
harmacological  and  surgical  therapies
espite  indications  that  hypersalivation  is  not  one  of  the
actors  responsible  for  sialorrhea  in  children  with  CP,  most
vailable  treatments  --  including  the  use  of  oral  (OR),  trans-
ermal  (TD),  and  sublingual  (SL)  medications,  botulinum
oxin,  or  surgical  management  --  aim  at  the  reduction  in
aliva  production.3
There  are  advantages  and  disadvantages  to  the  use  of
hese  techniques  (Table  3)  when  compared  with  nonpharma-
ological  and  nonsurgical  treatments.  In  general,  the  options
imed  at  reducing  salivary  production  quickly  lead  to  an
ffective  reduction  in  sialorrhea,  but  with  a  proﬁle  of  side
ffects  inherent  to  each  treatment  modality.  Another  impor-
ant  aspect  is  related  to  the  possible  exacerbation  of  GERD
nd  esophagitis.3 Therefore,  in  those  patients  undergoing  a
reatment  whose  mechanism  of  action  is  to  reduce  salivary
roduction,  early  and  effective  GERD  treatment  becomes
i
c
y
tssential.  In  this  group  of  treatments,  each  type  has  its
eculiarities,  as  described  below.
otulinum  toxin
he  intraglandular  injection  of  botulinum  toxin  inhibits  the
elease  of  acetylcholine  from  cholinergic  nerve  terminals,
hereby  reducing  salivary  secretion  and  sialorrhea.  Some
rospective,  controlled  studies  have  investigated  the  use  of
otulinum  toxin  type  A  (BoNTA)  for  the  treatment  of  sialor-
hea.  A  signiﬁcant  reduction  in  sialorrhea  was  observed  in
hese  studies  using  objective  (Class  I)  and  subjective  control
cales.  The  injection  sites  are  the  parotid  and  submandibular
lands.  Older  children  (cooperative)  and  adults  may  undergo
ocal  anesthesia.1,40,41 Some  disadvantages  (Table  3) hinder
atients’  access  to  the  procedure:  the  injection  sites  should
e  accessed,  ideally,  by  ultrasound;  the  technique  requires
he  presence  of  medical  and  nursing  staff  with  experience;
nd  it  should  be  assessed  whether  the  patient  meets  the
linical  requirements  to  undergo  sedation  or  anesthesia.
urgical  treatment
he  ﬁrst  surgical  treatment  for  sialorrhea  was  parotid  ductal
elocation,42 followed  by  further  removal  of  submandibular
lands.43,44 Radical  procedures  such  as  bilateral  division  of
he  parotid  ducts  with  removal  of  the  submandibular  glands
nd  neurectomies  have  been  proposed,  but  with  unpre-
ictable  results.43--48 Surgeries  were  carried  out  mostly  in
dults,  and  their  efﬁcacy  was  questionable,  as  symptoms
ecurred  after  some  time.43,44 In  1974,  Ekedahl  described  the
earrangement  of  ducts  from  the  submandibular  glands  into
he  tonsilar  fossa.49 The  glands  maintained  their  function
ith  normal  passage  of  saliva  to  the  oropharynx,  preventing
he  accumulation  of  saliva  in  the  anterior  mouth  ﬂoor,  ensur-
ng  the  presence  of  saliva  in  the  oral  cavity,  while  keeping  its
ontribution  to  the  swallowing  process.  Over  the  subsequent
ears,  it  has  undergone  few  modiﬁcations  (the  removal  of
he  sublingual  glands  is  performed  concomitantly)  and  it
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Table  4  Pharmacological  treatment.
Author  and
year
Drug  Associated
pathology
Ages  n  Study  design  Results  Side  effects
Mier  et  al.56 Glycopyrrolate  CP  and
other
neurological
conditions
4--19  years 39  DB,  PC Glycopyrrolate
0.10  mg/kg/dose  is
effective  for  the  control
of  sialorrhea
Incidence  of  20%  of  SE,
enough  to  withdraw  the
drug
Zeller et  al.55 Glycopyrrolate  CP  and
other
neurological
conditions
3--18  years 137  Uncontrolled
clinical  trial
Satisfactory  response  in
40.3%  of  patients  in  the
4th  week  and  52.3%  in
the  24th  week,  with  a
peak  of  56.7%  in  the
16th  week
Intestinal  constipation
(20.4%),  vomiting
(17.5%),  diarrhea
(17.5%),  pyrexia  (14.6%),
xerostomia  (10.9%),
ﬂushing  (10.9%),  nasal
congestion  (10.  9%)
Mato et  al.50 Scopolamine
TD
CP  and
other
neurological
conditions
12--58  years 30  Prospective,
randomized,
DB,  PC
Signiﬁcant  improvement
(p  <  0.005)  in  the
scopolamine  group
Incidence  of  23%  of  SE
(four  patients  with  more
severe  SE  and  three  with
milder  SE)
Camp-Bruno
et al.51
Benztropine  CP  4--44  years
(14  children/
adolescents
and  6  adults)
20  DB,  PC  Signiﬁcant  reduction  in
sialorrhea  when
compared  to  placebo
Incidence  of  11%  of  more
severe  SE  resolved  in
24--48  h  after  drug
withdrawal
Carranza-del
Rio et  al.57
Trihexyphenidyl  CP  1--18  years  70  Retrospective  Most  patients  (96%)
reported  some
improvement  in
sialorrhea
SE  were  found  in  69.3%
of  patients:  intestinal
constipation  (43),
urinary  retention  (19),
xerostomia  (seven),
blurred  vision  (ﬁve),
increase  in  involuntary
movements  (four)
reduction  in  seizure
control  (four),
hallucinations  (two)
De Simone
et  al.70
Atropine
sulfate  SL
Upper
digestive
tract  cancer
48--87  years 22  Prospective,
randomized,
DB,  PC
The  study  failed  to
demonstrate
effectiveness  of  atropine
sulfate  compared  to
placebo
Only  one  patient
(xerostomia)
DB, double-blind; CP, cerebral palsy; PC, placebo-controlled; SE, side effects.
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as  become  the  surgical  technique  of  choice  for  severe
ialorrhea.44,49 Due  to  the  risk  of  permanent  consequences
especially  xerostomia),  it  is  indicated  only  in  severe  cases,
hose  non-responsive  to  non-surgical  therapies  and  in  which
ialorrhea  has  great  impact  on  the  health  and  quality  of  life
f  the  children  and  family  members/caregivers.1
ral,  transdermal,  or  sublingual  drug  treatment
he  salivary  glands  are  controlled  by  the  parasympathetic
utonomic  nervous  system  and,  therefore,  anticholin-
rgic  drugs  induce  a  signiﬁcant  reduction  in  salivary
ow,  being  the  most  often  used  drugs.  The  advan-
ages  and  disadvantages  of  the  oral  (OR),  transdermal
TD),  or  sublingual  (SL)  use  of  anticholinergic  drugs  are
ummarized  in  Table  3.12,50--57 The  most  widely  used  sys-
emic  anticholinergic  drugs  are  glycopyrrolate,  benztropine,
copolamine,  atropine,  and  trihexyphenidyl;  however,  only
rihexyphenidyl  and  atropine  sulfate  are  available  in  Brazil;
he  results  of  some  studies  with  these  drugs  are  summarized
n  Table  4.
lycopyrrolate
he  oral  solution  of  glycopyrrolate  is  currently  the  only  for-
ulation  of  an  anticholinergic  drug  approved  by  the  United
tates  Food  and  Drug  Administration  (FDA)  to  treat  sial-
rrhea  in  children  aged  3--16  years.  Glycopyrrolate  is  not
vailable  in  Brazil.
copolamine
everal  studies  have  shown  a  reduction  in  saliva  secretion
ith  use  of  scopolamine.  The  transdermal  route  effectively
educes  salivary  secretion  in  approximately  67%  of  patients
nd  its  action  can  be  demonstrated  15  min  after  the  trans-
ermal  patch  is  applied.  The  main  side  effects  are  pupil
ilation  and  urinary  retention.53 Lewis  et  al.  observed  that
6%  of  the  patients  had  pupil  dilation,  which  occurred  a  few
ays  after  the  start  of  the  treatment.52
enztropine
here  has  been  only  one  study  with  benztropine  involving
hildren.  The  drug  was  considered  effective  in  a  controlled,
andomized  clinical  trial  published  by  Camp-Bruno  et  al.51
rihexyphenidyl
n  the  largest  study  in  children  with  trihexyphenidyl,  a
rug  commonly  used  in  the  treatment  of  extrapyramidal
yndromes  such  as  dystonia,  the  indications  for  use  were  dys-
onia  (28.7%),  sialorrhea  (5.9%),  and  dystonia  and  sialorrhea
65.4%).  The  initial  mean  dose  was  0.095  mg/kg/day  and
he  maximum  mean  dose  was  0.55  mg/kg/day,  two  to  three
imes  a  day.  Side  effects  were  found  in  69.3%  of  patients.
ost  patients  reported  some  improvement  in  dystonia,  sial-
rrhea,  and  speciﬁc  language.  The  authors  concluded  that
rihexyphenidyl  was  better  tolerated  in  this  population  of
hildren  and  adolescents  (with  CP  and  extrapyramidal  syn-
rome)  when  compared  to  the  adult  population,  and  that
mprovement  in  sialorrhea  may  have  occurred  due  to  the
nticholinergic  effect  of  the  drug,  but  also  through  cen-
ral  action,  resulting  in  greater  control  motor  of  muscles
nvolved  in  swallowing.57 Other  studies  have  reported  theScofano  Dias  BL  et  al.
uccessful  use  of  trihexyphenidyl  in  adults  to  treat  sialorrhea
nduced  by  clozapine.58--60
tropine  sulfate
lthough  atropine  has  been  for  many  years  acknowledged  as
ffective,  it  has  never  been  widely  accepted  for  the  treat-
ent  of  chronic  sialorrhea.54 The  ﬁrst  mention  of  its  use
or  treatment  of  sialorrhea  was  made  in  an  article  pub-
ished  in  October  1970  by  Smith  et  al.  in  the  New  England
ournal  of  Medicine.61 Subsequently,  some  studies  reported
ts  use  to  treat  drug-induced  sialorrhea62--68 and  patients
ith  Parkinson’s  disease.69 De  Simone  et  al.  published  the
nly  prospective,  randomized,  placebo-controlled,  double
lind  study  with  atropine  SL,  which  failed  to  demonstrate
ffectiveness  of  atropine  when  compared  to  placebo.70 In
010,  Rapoport  reported  the  case  of  14-year  old  boy  with
etachromatic  leukodystrophy  and  excess  oral  secretions
ho  needed  frequent  aspirations,  which  caused  recurrent
rops  in  oxygen  saturation  caused  by  saliva  aspiration,  suc-
essfully  treated  with  atropine  sulfate  SL,  representing  the
nly  reported  case  in  the  literature  on  atropine  sulfate  SL  in
hildren  or  adolescents.54
There  are  no  speciﬁc  studies  published  in  children  with
P,  but  there  is  ongoing  research  using  atropine  SL  (0.5%  eye
rops)  in  children  with  CP,  which  suggests  good  efﬁcacy  with
ow  incidence  of  side  effects.  Such  data  will  be  available  for
ublication  soon.
inal considerations
n  practice,  to  indicate  any  type  of  treatment  for  sialor-
hea  in  children  with  CP,  one  should  take  into  account  the
atient’s  access  to  the  proposed  treatment,  as  well  as  the
ocioeconomic  and  cultural  characteristics  of  each  family,
n  order  for  the  individual  choice  of  methods  to  be  efﬁ-
ient,  more  speciﬁc,  and  to  be  less  of  a  burden  for  each
atient/family.  The  most  effective  treatment  and  the  one
hat  effectively  addresses  the  cause  of  sialorrhea  in  chil-
ren  with  CP  is  training  of  sensory  awareness  and  oral  motor
kills,  performed  or  supervised  by  a  trained  and  qualiﬁed
peech  therapist.
Drug  therapies,  such  as  the  use  of  botulinum  toxin  and
nticholinergics,  have  a  transient  effect  and  should  ideally
e  adjuvant  to  speech  therapy,  or  should  be  considered  in
peciﬁc  cases  of  patients  with  moderate  to  severe  sialorrhea
r  respiratory  complications.  Among  the  available  drugs,
tropine  sulfate  is  a  low-cost,  easy-access  drug  and  appears
o  have  good  clinical  response  with  good  safety  proﬁle.  The
se  of  trihexyphenidyl  for  the  treatment  of  sialorrhea  in  chil-
ren  may  be  considered  for  dyskinetic  forms  of  CP  or  in  some
elected  cases.
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